ARTICLE | Clinical News

TG Therapeutics completes enrollment in Phase III UNITY-CLL trial

November 3, 2017 8:43 PM UTC

TG Therapeutics Inc. (NASDAQ:TGTX) completed enrollment in the Phase III UNITY-CLL trial evaluating ublituximab (TG-1101, TGTX-1101) in combination with TGR-1202 (umbralisib) to treat chronic lymphocytic leukemia (CLL).

The open-label, international trial is comparing IV ublituximab and oral TGR-1202 alone or in combination vs. IV Gazyva obinutuzumab plus oral chlorambucil in patients with both treatment naïve and relapsed or refractory CLL. Patients receive ublituximab on days 1, 8 and 15 followed by maintenance infusions and TGR-1202 once daily. The primary endpoint is progression-free survival (PFS) and the secondary endpoint is overall response rate (ORR). The company has now enrolled more than 200 patients in each of the two combination arms...

BCIQ Company Profiles


TG Therapeutics Inc.